Your browser doesn't support javascript.
Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT).
Mussini, Cristina; Falcone, Marco; Nozza, Silvia; Sagnelli, Caterina; Parrella, Roberto; Meschiari, Marianna; Petrosillo, Nicola; Mastroianni, Claudio; Cascio, Antonio; Iaria, Chiara; Galli, Massimo; Chirianni, Antonio; Sagnelli, Evangelista; Iacobello, Carmelo; Di Perri, Giovanni; Mazzotta, Francesco; Carosi, Giampiero; Tinelli, Marco; Grossi, Paolo; Armignacco, Orlando; Portelli, Vincenzo; Andreoni, Massimo; Tavio, Marcello.
  • Mussini C; Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy. Electronic address: crimuss@unimore.it.
  • Falcone M; Division of Infectious Diseases, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
  • Nozza S; Department of Infectious and Tropical Diseases, San Raffaele Hospital, Milan, Italy.
  • Sagnelli C; Department of Mental Health and Public Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
  • Parrella R; Respiratory Infectious Diseases Unit, Cotugno Hospital, AORN dei Colli, Naples, Italy.
  • Meschiari M; Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy.
  • Petrosillo N; Clinical and Research Department of Infectious Diseases, National Institute for Infectious Diseases 'L. Spallanzani', IRCCS, Rome, Italy.
  • Mastroianni C; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Cascio A; Infectious and Tropical Diseases Unit, Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy.
  • Iaria C; Infectious Disease Unit, ARNAS Civico - Di Cristina-Benfratelli Hospital, Palermo, Italy.
  • Galli M; Infectious Diseases Unit, Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.
  • Chirianni A; SIMIT, Milan, Italy.
  • Sagnelli E; SIMIT, Milan, Italy.
  • Iacobello C; Infectious Disease Unit, Cannizzaro Hospital, Catania, Italy.
  • Di Perri G; Clinic of Infectious Diseases, University of Turin, Turin, Italy.
  • Mazzotta F; SIMIT, Milan, Italy.
  • Carosi G; Infectious Diseases, University of Brescia, Brescia, Italy.
  • Tinelli M; Istituto Auxologico Italiano, IRCCS, San Luca Hospital, Milan, Italy.
  • Grossi P; Unit of Infectious and Tropical Diseases, ASST dei Sette Laghi, Department of Medicine and Surgery, University of Insubria, Varese, Italy.
  • Armignacco O; SIMIT, Milan, Italy.
  • Portelli V; SIMIT, Milan, Italy.
  • Andreoni M; Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy; Infectious Diseases Clinic, University Hospital "Tor Vergata", Rome, Italy.
  • Tavio M; Unit of Emerging and Immunosuppressed Infectious Diseases, Department of Gastroenterology and Transplantation, Polytechnic University of Marche, Ancona, Italy.
Clin Microbiol Infect ; 27(3): 389-395, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-996800
ABSTRACT
SCOPE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic, reaching almost one million death worldwide. At present standard treatment for coronavirus disease 2019 (COVID-19) is not well defined because the evidence, either from randomized or observational studies, with conflicting results, has led to rapid changes in treatment guidelines. Our aim was to narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and interpretation of the data by experts who are treating patients in the frontline setting.

METHODS:

The panel conducted a detailed review of the literature and eventual press releases from randomized clinical trials for each possible available treatment. Inductive PubMed search waws performed for publications relevant to the topic, including all clinical trials conducted. The result was a flowchart with treatment indications for patients with COVID-19. IMPLICATIONS After 6 months of a pandemic situation and before a possible second coronavirus wave descends on Europe, it is important to evaluate which drugs proved to be effective while also considering that results from many randomized clinical trials are still awaited. Indeed, among treatments for COVID-19, only glucocorticoids have resulted in an association with a significant decrease in mortality in published randomized controlled trials. New therapeutic strategies are urgently needed.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Societies, Medical / Practice Guidelines as Topic / COVID-19 Drug Treatment Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews Limits: Humans Country/Region as subject: Europa Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Societies, Medical / Practice Guidelines as Topic / COVID-19 Drug Treatment Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews Limits: Humans Country/Region as subject: Europa Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article